Nicotinamide Riboside

ID: nicotinamide_riboside

Aliases: NR, Niagen, nicotinamide riboside chloride

Type: compound

Route/form: oral supplement in most human trials; IV NR has limited emerging clinic data

Status: supplement

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, human_trial, review

Linked sources: 4

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, Gut / immune / inflammation, Longevity / mitochondrial / redox, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• NAD+ precursor
• NRK pathway
• NAD salvage metabolism
• sirtuin/PARP substrate supply hypothesis

Optimization domains

• NAD metabolism
• aging
• mitochondrial
• metabolic
• muscle
• cardiovascular health
• inflammation

Research basis

• NR has multiple human studies showing oral supplementation can raise NAD-related metabolites, including healthy older-adult and obese-male trial contexts.
• It belongs as a separate node from IV NAD+ and NMN because route, precursor chemistry, and human endpoint data differ.
• The strongest claim is NAD-metabolite modulation with mixed downstream clinical outcomes.

Limits, risks, and missing evidence

• Several human metabolic trials show biomarker movement without strong clinical benefit.
• Anti-aging, fat-loss, cognitive, and muscle-performance claims often outrun the evidence.
• Long-term tissue-specific NAD-pathway consequences and product identity still matter.

Risk flags

• supplement
• human biomarker support
• clinical outcome uncertain
• nad pathway

Linked papers, labels, and reviews

1. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
   human_rct / pubmed_nr_healthy_older_2018
   Randomized crossover human NR study; supports oral NAD+ metabolome elevation and tolerability, with exploratory cardiovascular/metabolic endpoints.
2. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects
   human_rct / pubmed_nr_obese_men_2018
   Direct human NR trial in obese insulin-resistant men; useful negative/limited-effect context for insulin sensitivity and fat-loss claims.
3. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures
   human_trial / pubmed_nr_aged_muscle_2019
   Aged human skeletal-muscle NR study; supports tissue NAD metabolome and transcriptomic signals, not a demonstrated hypertrophy or performance protocol.
4. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
   review / pubmed_nad_boosting_molecules_review_2018
   Broad NAD-boosting review covering NR, NMN, CD38, PARP, sirtuins, aging, metabolic disease, and translational caveats.